These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37078380)

  • 1. Postprandial dysfunction in fatty liver disease.
    Grandt J; Jensen AH; Werge MP; Rashu EB; Møller A; Junker AE; Hobolth L; Mortensen C; Johansen CD; Vyberg M; Serizawa RR; Møller S; Gluud LL; Wewer Albrechtsen NJ
    Physiol Rep; 2023 Apr; 11(8):e15653. PubMed ID: 37078380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
    Wewer Albrechtsen NJ; Junker AE; Christensen M; Hædersdal S; Wibrand F; Lund AM; Galsgaard KD; Holst JJ; Knop FK; Vilsbøll T
    Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G91-G96. PubMed ID: 28971838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
    Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
    Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
    Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
    PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
    Junker AE; Gluud LL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
    J Hepatol; 2016 Apr; 64(4):908-15. PubMed ID: 26626496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Liver-α-Cell Axis and Type 2 Diabetes.
    Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
    Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter.
    Chon YE; Kim KJ; Jung KS; Kim SU; Park JY; Kim do Y; Ahn SH; Chon CY; Chung JB; Park KH; Bae JC; Han KH
    Yonsei Med J; 2016 Jul; 57(4):885-92. PubMed ID: 27189281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes.
    Guerra S; Gastaldelli A
    Curr Opin Pharmacol; 2020 Dec; 55():165-174. PubMed ID: 33278735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meal-derived glucagon responses are related to lower hepatic phosphate concentrations in obesity and type 2 diabetes.
    Weber KS; Straßburger K; Fritsch M; Bierwagen A; Koliaki C; Phielix E; Pacini G; Hwang JH; Markgraf DF; Burkart V; Müssig K; Szendroedi J; Roden M
    Diabetes Metab; 2018 Nov; 44(5):444-448. PubMed ID: 29910091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.
    Polyzos SA; Perakakis N; Boutari C; Kountouras J; Ghaly W; Anastasilakis AD; Karagiannis A; Mantzoros CS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e390-400. PubMed ID: 31690932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone.
    Chai SY; Pan XY; Song KX; Huang YY; Li F; Cheng XY; Qu S
    Lipids Health Dis; 2014 Jan; 13():7. PubMed ID: 24397589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
    Ito A; Horie I; Miwa M; Sako A; Niri T; Nakashima Y; Shigeno R; Haraguchi A; Natsuda S; Akazawa S; Kamada A; Kawakami A; Abiru N
    J Diabetes Investig; 2021 Aug; 12(8):1367-1376. PubMed ID: 33369175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    Morio R; Hyogo H; Hatooka M; Morio K; Kan H; Kobayashi T; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Aikata H; Ochi H; Masayasu Y; Chayama K
    J Gastroenterol; 2017 Feb; 52(2):253-262. PubMed ID: 27351871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
    Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
    Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat.
    Musso G; Cassader M; De Michieli F; Paschetta E; Pinach S; Saba F; Bongiovanni D; Framarin L; Berrutti M; Leone N; Corvisieri S; Parente R; Molinaro F; Sircana A; Bo S; Gambino R
    Hum Mol Genet; 2017 May; 26(9):1747-1758. PubMed ID: 28334911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring.
    Oki Y; Ono M; Hyogo H; Ochi T; Munekage K; Nozaki Y; Hirose A; Masuda K; Mizuta H; Okamoto N; Saibara T
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):797-805. PubMed ID: 29634665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.